Praxis Precision Medicines, Inc.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Gilbert Ray Cisneros, Jr.House · D · CA |
PRAXPraxis Precision Medicines, Inc. · Stock |
Purchase $1,001 - $15,000 |
Oct 12, 2026 | Sep 29, 2026 | Filing ↗ |
Gilbert Ray Cisneros, Jr.House · D · CA |
PRAXPraxis Precision Medicines, Inc. · Stock |
Purchase $1,001 - $15,000 |
Sep 4, 2026 | Jul 30, 2026 | Filing ↗ |
Whale Activity
- Increased129
- New69
- Held38
- Decreased91
- Closed42
- No prior filing12
| Filer | Shares | Value | Change |
|---|---|---|---|
| Janus Henderson Group Ltd. | 3.4M | $1.00B | — |
| FMR LLC | 2.6M | $768.2M | increased |
| BlackRock, Inc. | 2.2M | $650.3M | decreased |
| PERCEPTIVE ADVISORS LLC | 2.0M | $589.7M | decreased |
| BAKER BROS. ADVISORS LP | 1.8M | $510.6M | held |
| Orbis Allan Gray Ltd | 1.4M | $396.1M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3M | $380.0M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $357.9M | decreased |
| STATE STREET CORP | 1.0M | $304.1M | increased |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 981.5K | $285.8M | decreased |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 963.4K | $280.6M | held |
| BANK OF AMERICA CORP /DE/ | 890.6K | $259.4M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Souza MarcioChief Executive Officer · Director | Gift | −2,600 | $0.00 | $0 | Jul 8, 2026 | Form 4 ↗ |
| Souza MarcioChief Executive Officer · Director | Gift | −20.5K | $0.00 | $0 | Jul 8, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Sale | −837 | $315.71 | $264K | Jun 24, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Sale | −1,279 | $314.90 | $403K | Jun 24, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Sale | −504 | $313.66 | $158K | Jun 24, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Sale | −1,004 | $312.83 | $314K | Jun 24, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Sale | −2,854 | $311.91 | $890K | Jun 24, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Sale | −1,750 | $310.89 | $544K | Jun 24, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Sale | −999 | $309.38 | $309K | Jun 24, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Sale | −1,240 | $308.24 | $382K | Jun 24, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Sale | −683 | $306.77 | $210K | Jun 24, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Sale | −320 | $305.31 | $98K | Jun 24, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Sale | −120 | $303.13 | $36K | Jun 24, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Sale | −10 | $301.44 | $3K | Jun 24, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Option exercise | +3,034 | $147.30 | $447K | Jun 24, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Option exercise | +8,566 | $44.25 | $379K | Jun 24, 2026 | Form 4 ↗ |
| Arbuckle Stuart ADirector | Grant / award | +1,371 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| Chodakewitz JeffreyDirector | Grant / award | +1,371 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| YOUNG WILLIAM DDirector | Grant / award | +1,371 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| DeSimone JillDirector | Grant / award | +1,371 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 885.4K | $296.4M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 653.1K | $218.7M | 0.26% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 639.6K | $214.1M | 0.11% | Jun 30, 2026 |
| Select Biotechnology Portfolio Fidelity Select Portfolios | 411.4K | $144.1M | 2.29% | Aug 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 413.7K | $138.5M | 1.29% | Jun 30, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 405.0K | $135.6M | 0.20% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund Janus Investment Fund | 379.4K | $127.0M | 2.19% | Jun 30, 2026 |
| Janus Henderson Enterprise Fund Janus Investment Fund | 358.1K | $119.9M | 0.54% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 300.9K | $100.7M | 0.10% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 274.8K | $84.6M | 0.25% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list PRAX's shares (CUSIP 74006W207), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Allan Gray Australia Pty LtdSCHEDULE 13G/A · passive (13G) · 3,770 shares0.0%
Nov 16, 2026 · ↗ - ORBIS INVESTMENT MANAGEMENT LTDSCHEDULE 13G/A · passive (13G) · 1.4M shares4.9%
Nov 16, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 2.6M shares9.2%
Nov 5, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 2.6M shares9.2%
Nov 5, 2026 · ↗ - Allan Gray Australia Pty LtdSCHEDULE 13G/A · passive (13G) · 3,108 shares0.0%
Aug 14, 2026 · ↗ - ORBIS INVESTMENT MANAGEMENT LTDSCHEDULE 13G/A · passive (13G) · 1.5M shares5.5%
Aug 14, 2026 · ↗ - Felix J. BakerSCHEDULE 13G · passive (13G) · 1.8M shares6.3%
May 15, 2026 · ↗ - Julian C. BakerSCHEDULE 13G · passive (13G) · 1.8M shares6.3%
May 15, 2026 · ↗ - Baker Bros. Advisors (GP) LLCSCHEDULE 13G · passive (13G) · 1.8M shares6.3%
May 15, 2026 · ↗ - Baker Bros. Advisors LPSCHEDULE 13G · passive (13G) · 1.8M shares6.3%
May 15, 2026 · ↗
Corporate Lobbying
- THE KPM GROUP DC LLCPRAXIS PRECISION MEDICINES · 2026 Q3 · PHA$40K
Filing ↗ - BALLARD PARTNERS, LLCPRAXIS PRECISION MEDICINES, INC. · 2026 Q3 · HCR$120K
Filing ↗ - BALLARD PARTNERSPRAXIS PRECISION MEDICINES, INC. · 2026 Q3 · HCR—
Filing ↗ - THE KPM GROUP DC LLCPRAXIS PRECISION MEDICINES · 2026 Q2 · PHA$40K
Filing ↗ - THE KPM GROUP DC LLCPRAXIS PRECISION MEDICINES · 2026 Q2 · PHA$40K
Filing ↗
Government Contracts
No federal contract awards found for Praxis Precision Medicines, Inc..
U.S. Patents
No USPTO patent applications found for Praxis Precision Medicines, Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $8.6M | $2.4M | $0 | n/a |
| Operating income | -$326.2M | -$200.2M | -$126.4M | -$215.0M | -$167.3M |
| Net income | -$303.3M | -$182.8M | -$123.3M | -$214.0M | -$167.1M |
| Diluted EPS | -$13.48 | -$10.21 | -$18.69 | -$69.65 | -$3.94 |
| Operating cash flow | -$249.1M | -$131.8M | -$111.1M | -$185.0M | -$124.6M |
| Cash and equivalents | $357.3M | $215.4M | $81.3M | $61.6M | $138.7M |
| Total assets | $937.9M | $483.1M | $87.9M | $115.1M | $292.7M |
| Total liabilities | $59.8M | $37.7M | $18.3M | $39.0M | $41.9M |
| Shareholders' equity | $878.1M | $445.4M | $69.7M | $76.1M | $250.8M |
As Praxis Precision Medicines, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 19, 2026 ↗
Stock Splits
- 1-for-15Reverse splitNov 29, 2023
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsNov 12, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsNov 9, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureAug 6, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsJul 7, 2026
EDGAR ↗ - 8-K · Items 4.01, 9.01Change in auditorJul 2, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsJun 29, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsJun 22, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 12, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsJun 1, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureMay 7, 2026
EDGAR ↗

